

10/031367

=> s l1

SAMPLE SEARCH INITIATED 17:02:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4011 TO ITERATE

24.9% PROCESSED 1000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 76424 TO 84016
PROJECTED ANSWERS: 1 TO 200

L2 1 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 17:02:11 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 80442 TO ITERATE

100.0% PROCESSED 80442 ITERATIONS 106 ANSWERS
SEARCH TIME: 00.00.02

L3 106 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
148.15	148.78

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 17:02:20 ON 18 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 May 2003 VOL 138 ISS 21
FILE LAST UPDATED: 16 May 2003 (20030516/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 25 L3

=> d l4 1-24 bib abs hitstr

L4. ANSWER 1 OF 25 CAPLUS COPYRIGHT 2003 ACS

AN 2003:282118 CAPLUS

DN 138:304300

TI Preparation and antiviral activity of substituted
piperazinyloxoacetylindole derivativesIN Wallace, Owen B.; Wang, Tao; Yeung, Kap-Sun; Pearce, Bradley C.; Meanwell,
Nicholas A.; Qiu, Zhilei; Fang, Haiquan; Xue, Qiufen May; Yin, Zhiwei

PA USA

SO U.S. Pat. Appl. Publ., 182 pp., Cont.-in-part of U.S. Ser. No. 888,686.

CODEN: USXXCO


DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003069245	A1	20030410	US 2001-27612	20011219
PRAI	US 2000-217444P	P	20000710		
	US 2001-265978P	P	20010202		
	US 2001-888686	A2	20010625		

GI



AB Piperazinyloxoacetylindole derivs., e.g. I (R = Ph), were prep'd. and tested as human antiviral agents, specifically to be used for treating HIV and AIDS. Thus, bromoindole I (R = Br) (II) reacted with tri-n-butylphenyltin to give I (R = Ph). Furthermore, II was prep'd. by reacting 2-bromo-5-fluoronitrobenzene with vinylmagnesium bromide, which gave 4-fluoro-7-bromoindole. The latter comp'd. was then added to Et chlorooxoacetate to give the acylated adduct which was hydrolyzed to the acid and aminated with N-benzoylpiperazine. Testing of these comp'ds. indicated that they possess unique antiviral activity; and they are proposed to be used alone or in combination with other antivirals, anti-infectives, immunomodulators or HIV entry inhibitors.

IT **389629-30-5P**, 1-(4-Benzoyl-2-(R)-methylpiperazin-1-yl)-2-[7-(4-benzylpiperazine-1-carbonyl)-1H-indol-3-yl]ethane-1,2-dione
389629-31-6P, 1-[7-(4-Benzoylpiperazine-1-carbonyl)-4-fluoro-1H-indol-3-yl]-2-(4-benzoylpiperazin-1-yl)ethane-1,2-dione

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperazinyloxoacetylindole derivs. and their use as human antiviral, anti-infective, anti-HIV, anti-AIDS, and immunomodulator agents)


RN 389629-30-5 CAPLUS

CN Piperazine, 4-benzoyl-2-methyl-1-[oxo[7-[[4-(phenylmethyl)-1-

10/031367


piperazinyl]carbonyl]-1H-indol-3-yl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 389629-31-6 CAPLUS

CN Piperazine, 1-benzoyl-4-[[7-[(4-benzoyl-1-piperazinyl)carbonyl]-4-fluoro-1H-indol-3-yl]oxoacetyl]- (9CI) (CA INDEX NAME)



10/031367

L4 ANSWER 2 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 2002:869496 CAPLUS
DN 137:363033
TI Peptidomimetic modulators of cell adhesion
IN Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang;
Michaud, Stephanie D.; Wang, Shoameng; Hu, Zenjian
PA Can.
SO U.S. Pat. Appl. Publ., 309 pp., Cont.-in-part of U.S. Ser. No. 491,078.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002168761	A1	20021114	US 2001-769145	20010124
PRAI	US 2000-491078	A2	20000124		
OS	MARPAT 137:363033				


AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

IT 351858-51-0, Piperazine, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(1H-indol-6-ylcarbonyl)-
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

RN 351858-51-0 CAPLUS

CN Piperazine, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(1H-indol-6-ylcarbonyl)-
(9CI) (CA INDEX NAME)



10/031367

L4 ANSWER 3 OF 25 CAPLUS COPYRIGHT 2003 ACS

AN 2002:552196 CAPLUS

DN 137:109296

TI Procedure for the production of (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenylethyl)piperazin-1-yl]methanone and its salts

IN Crassier, Helene; Boettcher, Henning; Eckert, Uwe; Bathe, Andreas; Emmert, Steffen

PA Merck Patent G.m.b.H., Germany

SO Ger. Offen., 12 pp.

CODEN: GWXXBX






DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10102944	A1	20020725	DE 2001-10102944	20010123
	WO 2002059092	A1	20020801	WO 2001-EP15240	20011221
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	DE 2001-10102944	A	20010123		
OS	CASREACT 137:109296				
GI					

Later




AB Title compd. I and its salts were prepd. by (1) formylation of an indolecarboxylic acid ester II (R = C1-6 alkyl, arylalkyl), (2) reacting of the resulting formylindolecarboxylic acid ester III (R as above) with NH₂OH to give an oxime deriv. IV (R as above), (3) conversion of the latter to a cyanoindolecarboxylic acid ester V (R as above), (4) sapon. of V to 3-cyano-1H-indole-7-carboxylic acid, (5) reaction of the latter with 1-[2-(4-fluorophenyl)ethyl]piperazine or its salts to give I, and (6) treatment with an acid to give a salt of I. Thus, a formylation mixt. of DMF and POCl₃ was treated slowly with 1H-indole-7-carboxylic acid Me ester in DMF at <30.degree. followed by heating at 100.degree. to give 89.9% 3-formyl-1H-indole-7-carboxylic acid Me ester which was heated with NH₂OH.HCl in DMF at 125.degree. for 1 h to give 3-(hydroxyiminomethyl)-1H-indole-7-carboxylic acid Me ester. The latter in PhMe was refluxed with SO₂Cl₂ to give 3-cyano-1H-indole-7-carboxylic acid Me ester which was sapond. in MeOH with NaOH to 3-cyano-1H-indole-7-carboxylic acid. A mixt. of 3-cyano-1H-indole-7-carboxylic acid in N-methylpyrrolidone and N,N-carbonyldiimidazole was stirred for 1 h at room temp. followed by addn. of 1-[2-(4-fluorophenyl)ethyl]piperazine to give I which was treated in AcMe with HCl to give 69% 7-(4-[2-(4-fluorophenyl)ethyl]piperazine-1-carbonyl)-1H-indole-3-carbonitrile hydrochloride. I are 5-HT_{2A} antagonists (no data).

IT 443144-26-1P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(procedure for the prodn. of (cyanoindolyl)[(fluorophenylethyl)piperazinyl]methanone and its salts)

RN 443144-26-1 CAPLUS

CN Piperazine, 1-[(3-cyano-1H-indol-7-yl)carbonyl]-4-[2-(4-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)



IT 443144-27-2P


RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

10/031367

(procedure for the prodn. of (cyanoindolyl)[(fluorophenylethyl)piperazi
nyl]methanone and its salts)

RN 443144-27-2 CAPLUS

CN Piperazine, 1-[(3-cyano-1H-indol-7-yl)carbonyl]-4-[2-(4-
fluorophenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



10/031367

L4 ANSWER 4 OF 25 CAPLUS COPYRIGHT 2003 ACS

AN 2002:450255 CAPLUS

DN 137:17431

TI Geranylgeranyl transferase inhibitor screening assay

IN Eng, Wai-si; Lobell, Robert B.; Lumma, William C.; Smith, Anthony M.

PA USA

SO U.S. Pat. Appl. Publ., 42 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002072081	A1	20020613	US 2001-947903	20010906

PRAI	US 2000-230270P	P	20000906		
------	-----------------	---	----------	--	--

OS MARPAT 137:17431

AB The invention concerns a GGTase-I competitive binding assay which can be used to det. the relative GGTase-I inhibitory potency of test compds. The present invention is also directed toward radiolabeled geranylgeranyl-protein transferase type-I inhibitor compds. which are useful to label GGTase-I in assays, whether cell-based, tissue-based or in whole animal.


IT 290819-45-3

RL: ARG (Analytical reagent use); PAC (Pharmacological activity); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(geranylgeranyl transferase inhibitor screening assay)

RN 290819-45-3 CAPLUS


CN Piperazine, 1-[[1-[(4-cyanophenyl)methyl]-1H-imidazol-5-yl]methyl]-4-(1H-indol-4-ylcarbonyl)- (9CI) (CA INDEX NAME)



10/031367

L4 ANSWER 5 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 2002:408665 CAPLUS
DN 136:401784
TI Preparation of piperidinylcarbonyl- and piperazinylcarbonylindolylglyoxylates and -amides as inhibitors of p38-.alpha. kinase
IN Dugar, Sundeeep; Luedtke, Gregory; Tan, Xuefei
PA Scios Inc., USA
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002042292	A2	20020530	WO 2001-US43441	20011120
	WO 2002042292	A3	20021017		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002026911	A5	20020603	AU 2002-26911	20011120
	US 2003092717	A1	20030515	US 2001-990187	20011120
PRAI	US 2000-252197P	P	20001120		
	WO 2001-US43441	W	20011120		
OS	MARPAT 136:401784				
GI					



AB [Title compds. I; dotted line = optional double bond; B = WiCOXjY; Y = COR2, isostere thereof; R2 = H, noninterfering substituent; W, X = spacer of 2-6 .ANG.; i, j = 0, 1; R3 = noninterfering substituent; n = 0-3; Z3 = NR7, O; R7 = H, noninterfering substituent; 1 Z2 = C, CR8A, the other = CR1, C(R1)2, NR6, N; R1, R6, R8 = H, noninterfering substituent; A = Q1; Z1 = CR5, N; R5 = H, noninterfering substituent; p, q = 0-2; p+q = 0-3; Ar = aryl group substituted with 0-5 noninterfering substituents, wherein two noninterfering substituents can form a fused ring; R4 = noninterfering

10/031367

substituent; m is 0-4; L1, L2 = linker; the distance between the atom of Ar linked to L2 and the center of the Z2-contg. ring = 4.5-24.ANG.], were prepd. as inhibitors of p38-.alpha. kinase (no data). Thus, title compd. (II) was prepd. in several steps starting from 4-nitrophenylglyoxylic acid.

IT 309915-13-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperidinylcarbonyl- and piperazinylcarbonylindolylglyoxylates and -amides as inhibitors of p38-.alpha. kinase)

RN 309915-13-7 CAPLUS

CN 1H-Indole-3-acetamide, 6-chloro-5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N,N,1-trimethyl-.alpha.-oxo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 309915-14-8 309915-15-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of piperidinylcarbonyl- and piperazinylcarbonylindolylglyoxylates and -amides as inhibitors of p38-.alpha. kinase)

RN 309915-14-8 CAPLUS


CN 1H-Indole-3-acetamide, 5-[[[(4-fluorophenyl)methyl]-3-oxo-1-piperazinyl]carbonyl]-6-methoxy-N,N-dimethyl-.alpha.-oxo- (9CI) (CA INDEX NAME)



RN 309915-15-9 CAPLUS

CN 1H-Indole-3-acetamide, 5-[[[(2R,5S)-2,5-dimethyl-4-(1-phenylethyl)-1-piperazinyl]carbonyl]-6-methoxy-N,N-dimethyl-.alpha.-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 309915-24-0P 309915-38-6P 309915-41-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of piperidinylcarbonyl- and piperazinylcarbonylindolylglyoxylates and -amides as inhibitors of p38-.alpha. kinase)

RN 309915-24-0 CAPLUS


CN Piperazine, 1-[(6-chloro-1-methyl-1H-indol-5-yl)carbonyl]-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-, (2R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 309915-38-6 CAPLUS

CN Piperazinone, 1-[(4-fluorophenyl)methyl]-4-[(6-methoxy-1H-indol-5-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 309915-41-1 CAPLUS

CN Piperazine, 1-[(6-methoxy-1H-indol-5-yl)carbonyl]-2,5-dimethyl-4-(1-phenylethyl)-, (2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/031367



10/031367

L4 ANSWER 6 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 2002:66850 CAPLUS
DN 136:118472
TI Preparation of benzimidazole-5-carboxamides and indole-5-carboxamides to
treat cardiac failure and other disorders
IN Mavunkel, Babu J.; Lewicki, John A.; Liu, David Y.; Schreiner, George F.;
Perumattam, John J.
PA Scios, Inc., USA
SO U.S., 27 pp., Cont.-in-part of U.S. 6,130,235.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6340685	B1	20020122	US 1999-275176	19990324
	US 6130235	A	20001010	US 1998-128137	19980803
	WO 9961426	A1	19991202	WO 1999-US11222	19990521
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9940920	A1	19991213	AU 1999-40920	19990521
	BR 9911069	A	20010206	BR 1999-11069	19990521
	EP 1080078	A1	20010307	EP 1999-924412	19990521
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002516314	T2	20020604	JP 2000-550832	19990521
	WO 2000059904	A2	20001012	WO 2000-US7934	20000324
	WO 2000059904	A3	20010111		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6448257	B1	20020910	US 2000-535316	20000324
	NO 2000005881	A	20010109	NO 2000-5881	20001121
	US 2003073699	A1	20030417	US 2002-76131	20020213
PRAI	US 1998-86531P	P	19980522		
	US 1998-128137	A2	19980803		
	US 1999-275176	A	19990324		
	US 1999-316761	A	19990521		
	WO 1999-US11222	W	19990521		
OS	MARPAT 136:118472				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I-IV; Z1, Z2 = CR4, N; R4 = H, (un)substituted alkyl

optionally including one or more heteroatoms selected from O, S and N; or two R4 taken together form a bridge optionally contg. a heteroatom; R1 = V (wherein X1 = CO or an isostere thereof; m = 0-1; Y = (un)substituted alkyl, aryl, arylalkyl or two Y taken together may form an alkylene bridge; n = 0-2; Z3 = CH, N; X2 = CH, CH2 or an isostere thereof; Ar consists of one or two (un)substituted Ph moieties directly coupled to X2); R2 = H, (un)substituted alkyl optionally including one heteroatom which is O, S or N; R3 = H, halo, NO2, etc.], useful in treating inflammation, were prep'd. Thus, amidation of benzimidazole-5-carboxylic acid with tert-Bu 1-piperazinecarboxylate (86%) followed by deprotection (100%), and reaction of the resulting amide with 2,6-difluorobenzyl bromide afforded VI. Compds. I were found to inhibit p38 kinase, in particular, p38 kinase .alpha. (data given) and are thus useful in treating diseases mediated by this enzyme.


IT 251106-48-6P 251106-62-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of benzimidazole-5-carboxamides and indole-5-carboxamides to treat cardiac failure and other disorders)


RN 251106-48-6 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)methyl]-4-[[1-(1-methylethyl)-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 251106-62-4 CAPLUS

CN Piperazine, 1-[(1-ethyl-1H-indol-5-yl)carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT 251107-28-5


RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of benzimidazole-5-carboxamides and indole-5-carboxamides to treat cardiac failure and other disorders)

RN 251107-28-5 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)methyl]-4-(1H-indol-5-ylcarbonyl)- (9CI) (CA INDEX NAME)

10/031367




homolog

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/031367

L4 ANSWER 7 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 2002:51452 CAPLUS
DN 136:118470
TI Preparation of substituted indoleoxoacetyl piperazines with antiviral activity against HIV-1
IN Wallace, Owen B.; Wang, Tao; Yeung, Kap-Sun; Pearce, Bradley C.; Meanwell, Nicholas A.; Qiu, Zhilei; Fang, Haiquan; Xue, Qiufen May; Yin, Zhiwei
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 277 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004440	A1	20020117	WO 2001-US20300	20010626
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1299382	A1	20030409	EP 2001-946715	20010626
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	US 2000-217444P	P	20000710		
	US 2001-265978P	P	20010202		
	WO 2001-US20300	W	20010626		
OS	MARPAT 136:118470				
GI					



AB Indoleoxoacetyl piperazines I [A = (un)substituted alkoxy, aryl, heteroaryl; W = (un)substituted piperazino; R1 = H; R2-R5 = H, halogen, CN, NO2, (un)substituted NH2, OH, (un)substituted alkyl, cycloalkyl, alkoxy, CO2H, acyl, carbamoyl, amidino, aryl, heteroaryl, heterocyclic; R6 = H, alkyl] and their 2,3-dihydroindole analogs were prep'd. for use as virucides in the treatment of HIV and AIDS. Thus, 2-bromo-5-fluoronitrobenzene was cyclized with CH2:CHMgBr to give 4-fluoro-7-bromoindole, which was treated with ClCOCO2Et, followed by ester hydrolysis to give 4-fluoro-7-bromo-3-indoleglyoxylic acid. This acid was amidated with N-benzoylpiperazine and treated with PhSnBu3 to give I [A = R5 = Ph, W = piperazino, R1, R3, R4, R6 = H, R2 = F]. This comp'd. gave >98% inhibition of HIV-1 infection in HeLa cells.

IT 389629-30-5P 389629-31-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

10/031367


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted indoleoxoacetylpiperazines with antiviral activity against HIV-1)

RN 389629-30-5 CAPLUS


CN Piperazine, 4-benzoyl-2-methyl-1-[oxo[7-[[4-(phenylmethyl)-1-piperazinyl]carbonyl]-1H-indol-3-yl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 389629-31-6 CAPLUS

CN Piperazine, 1-benzoyl-4-[[7-[[4-benzoyl-1-piperazinyl]carbonyl]-4-fluoro-1H-indol-3-yl]oxoacetyl]- (9CI) (CA INDEX NAME)




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/031367

L4 ANSWER 8 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 2001:581832 CAPLUS
DN 135:166842
TI Preparation of (1H-indol-5-yl)methanones, 2-(2-fluorophenyl)acetamides and
2-(pyrazol-1-yl)pyrimidines as InhA inhibitors
IN Staveski, Mark M.; Sneddon, Scott F.; Yee, Christopher; Janjigian, Andrew
PA Genzyme Corporation, USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001056974	A2	20010809	WO 2001-US40045	20010206
	WO 2001056974	A3	20020718		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6372752	B1	20020416	US 2000-499183	20000207
PRAI	US 2000-499183	A1	20000207		
OS	MARPAT 135:166842				
GI					



AB The title compds. [I-III, etc.; R1 = (un)substituted heteroaryl, piperazinyl, piperidinyl, etc.; R2 = OH, (un)substituted aryl, cycloalkyl, etc.; n = 1-2; R3 = (un)substituted Ph, heteroaryl; R4 = H, halo, alkyl, etc.] which inhibit the Mycobacterial enoyl-ACP reductase required for cell wall biosynthesis, and are useful for treating a bacterial infection in a patient, were prepd. Thus, reacting 2-fluorophenylacetic acid with 4-chlorophenethylamine in the presence of DMAP and EDCI in CH₂Cl₂ afforded II [R2 = 4-ClC₆H₄; n = 2] which showed 82% InhA inhibition at 40 .mu.M.

IT 353522-46-0P 353522-48-2P 353522-54-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

10/031367

(prepn. of (1H-indol-5-yl)methanones, 2-(2-fluorophenyl)acetamides and 2-(pyrazol-1-yl)pyrimidines as InhA inhibitors)


RN 353522-46-0 CAPLUS

CN Piperazine, 1-(1H-indol-5-ylcarbonyl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 353522-48-2 CAPLUS

CN Piperazine, 1-(diphenylmethyl)-4-(1H-indol-5-ylcarbonyl)- (9CI) (CA INDEX NAME)



RN 353522-54-0 CAPLUS

CN Piperazine, 1-(1,3-benzodioxol-5-ylmethyl)-4-(1H-indol-5-ylcarbonyl)- (9CI) (CA INDEX NAME)



10/031367

L4 ANSWER 9 OF 25 CAPLUS COPYRIGHT 2003 ACS

AN 2001:545724 CAPLUS

DN 135:147398

TI Peptidomimetic modulators of cell adhesion

IN Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie Denise; Wang, Shoameng; Hu, Zengjian

PA Adherex Technologies, Inc., Can.

SO PCT Int. Appl., 416 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001053331	A2	20010726	WO 2001-US2508	20010124
	WO 2001053331	A3	20020711		
	WO 2001053331	C2	20021031		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-491078 A 20000124

OS MARPAT 135:147398


AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

IT 351858-51-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptidomimetic modulators of cell adhesion)

RN 351858-51-0 CAPLUS

CN Piperazine, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(1H-indol-6-ylcarbonyl)-(9CI) (CA INDEX NAME)



10/031367

L4 ANSWER 10 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 2001:247178 CAPLUS
DN 134:275776
TI Method using a geranylgeranyl-protein transferase inhibitor for preventing osteoporosis, pharmaceutical compositions, and compound preparation
IN Reszka, Alfred A.; Rodan, Gideon A.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 210 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001022963	A1	20010405	WO 2000-US26357	20000925
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 1999-156234P P 19990927

OS MARPAT 134:275776

AB A method for preventing or inhibiting bone resorption in a mammal comprises administering to a mammal in need thereof a therapeutically effective amt. of an inhibitor of geranylgeranyl-protein transferase type I.


IT 290819-45-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(geranylgeranyl-protein transferase inhibitor for preventing bone resorption, pharmaceutical compns., and compd. prepn.)

RN 290819-45-3 CAPLUS

CN Piperazine, 1-[[1-[(4-cyanophenyl)methyl]-1H-imidazol-5-yl]methyl]-4-(1H-indol-4-ylcarbonyl)- (9CI) (CA INDEX NAME)





10/031367

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/031367

L4 ANSWER 11 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 2001:78383 CAPLUS
DN 134:163059
TI Substituted piperazinone derivatives and other oxoazaheterocycl
compounds useful as factor Xa/IIa inhibitors
IN Ewing, William R.; Becker, Michael R.; Choi-Sledeski, Yong Mi; Pauls,
Heinz W.; He, Wei; Condon, Stephen M.; Davis, Roderick S.; Hanney, Barbara
A.; Spada, Alfred P.; Burns, Christopher J.; Jiang, John Z.; Li, Aiwen;
Myers, Michael R.; Lau, Wan F.; Poli, Gregory B.
PA Aventis Pharmaceuticals Products Inc., USA
SO PCT Int. Appl., 460 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001007436	A2	20010201	WO 2000-IB1156	20000726
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	BR 2000013179	A	20020402	BR 2000-13179	20000726
	EP 1208097	A2	20020529	EP 2000-951781	20000726
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	JP 2003508353	T2	20030304	JP 2001-512520	20000726
	NO 2002000214	A	20020402	NO 2002-214	20020115
	BG 106340	A	20021031	BG 2002-106340	20020122
PRAI	US 1999-363196	A	19990728		
	WO 2000-IB1156	W	20000726		
OS	MARPAT 134:163059				
GI					



AB The invention is directed to piperazinones I and their pharmaceutically acceptable salts, prodrugs, N-oxides, hydrates, and solvates [wherein A = CH or N; G1 and G2 = L1Cy1 or L2Cy2; Cy1 and Cy2 = (un)substituted aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, etc.; L1 = null, O, S, SO, SO2, or (un)substituted sulfamoyl, methylene, (alkyl)keto(alkyl), carbamoyl, etc.; L2 = null or linking group; R1, R1a, R2, R2a, R3, R3a, R4, R4a = independently H, carboxy, alkoxycarbonyl, alkyl, (hetero)aryl, aralkyl, heteroarylalkyl, etc.; m and n = independently 0-2]. The compds. inhibit factor Xa (no data) and factor IIa, and thereby the prodn. of thrombin, and are thus useful as anticoagulants in the treatment of a wide variety of conditions. The invention is also directed to pharmaceutical compns., synthetic intermediates, and a method of inhibiting factor Xa. Examples include the synthesis of approx. 1600 invention compds. and several hundred intermediates. For instance, condensation of 5-chloro-2-thienyloxyacetic acid with the corresponding N-benzyloxycarbonyl-protected piperazinone deriv. (prepn. given), using DIPEA and TBTU in DMF, gave II.


IT 234102-35-3P 234102-92-2P 234103-21-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of piperazinone derivs. and other substituted oxoazaheterocyclyl compds. as factor Xa/IIa inhibitors)

RN 234102-35-3 CAPLUS


CN Piperazinone, 1-[(4-amino-7-quinazolinyl)methyl]-4-[(3-chloro-1H-indol-6-yl)carbonyl]- (9CI) (CA INDEX NAME)



RN 234102-92-2 CAPLUS

CN Piperazinone, 1-[(4-amino-7-quinazolinyl)methyl]-4-[(3-chloro-1H-indol-6-yl)carbonyl]-3-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234103-21-0 CAPLUS

CN Piperazinone, 1-[(4-amino-7-quinazolinyl)methyl]-4-[(3-chloro-1H-indol-6-yl)carbonyl]-3-ethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/031367




10/031367

L4 ANSWER 12 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 2001:78382 CAPLUS
DN 134:131549
TI Preparation of piperazinyl indolyl methanones as 5-HT_{2A} receptor antagonists.
IN Bottcher, Henning; Marz, Joachim; Greiner, Hartmut; Harting, Jurgen; Bartoszyk, Gerd; Seyfried, Christoph; Van Amsterdam, Christoph
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001007434	A2	20010201	WO 2000-EP6463	20000707
	WO 2001007434	A3	20020516		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	DE 19934432	A1	20010201	DE 1999-19934432	19990722
	BR 2000012575	A	20020416	BR 2000-12575	20000707
	EP 1228041	A2	20020807	EP 2000-954447	20000707
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	JP 2003505457	T2	20030212	JP 2001-512518	20000707
	NO 2002000306	A	20020321	NO 2002-306	20020121
PRAI	DE 1999-19934432	A	19990722		
	WO 2000-EP6463	W	20000707		
OS	MARPAT 134:131549				
GI					

10/031566



AB Title compds. [I; R₁, R₃ = (substituted) Ph, unsatd. heterocycllyl], were prepd. as 5-HT_{2A} receptor antagonists (no data). Thus, 4-carboxy-3-(4-chlorobenzoyl)indole, 2-chloro-1-methylpyridinium iodide, N-methylpyrrolidine, N-phenethylpiperazine, and EtN(CHMe)₂ were stirred together for 3 h to give [3-(4-chlorobenzoyl)-1H-indol-4-yl]-(4-phenethylpiperazin-1-yl)methanone hydrochloride. I are potent 5-HT_{2A} antagonists and are suitable for the treatment of psychosis, schizophrenia, depression, neurol. disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders, e.g. nervous bulimia and anorexia, and premenstrual syndrome and/or for pos. influencing compulsive behaviors (obsessive-compulsive disorder, OCD).


10/031367

IT 321913-31-9P 321913-32-0P 321913-33-1P
321913-34-2P 321913-35-3P 321913-36-4P
321913-37-5P 321913-38-6P 321913-39-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of piperazinyl indolyl methanones as 5-HT_{2A} receptor antagonists)

RN 321913-31-9 CAPLUS


CN Piperazine, 1-[[3-(4-chlorobenzoyl)-1H-indol-4-yl]carbonyl]-4-(2-phenylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 321913-32-0 CAPLUS

CN Piperazine, 1-[[3-(4-fluorobenzoyl)-1H-indol-4-yl]carbonyl]-4-(2-phenylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

10/031367


RN 321913-33-1 CAPLUS

CN Piperazine, 1-[[3-(4-chlorobenzoyl)-1H-indol-4-yl]carbonyl]-4-[2-(4-fluorophenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

RN 321913-34-2 CAPLUS

CN Piperazine, 1-[[3-(4-fluorobenzoyl)-1H-indol-5-yl]carbonyl]-4-(2-phenylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


10/031367



● HCl


RN 321913-35-3 CAPLUS

CN Piperazine, 1-[[3-(4-chlorobenzoyl)-1H-indol-5-yl]carbonyl]-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 321913-36-4 CAPLUS

CN Piperazine, 1-[[3-(4-fluorobenzoyl)-1H-indol-5-yl]carbonyl]-4-[2-(4-fluorophenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 321913-37-5 CAPLUS


CN Piperazine, 1-[[3-(2-furanyl)-1H-indol-5-yl]carbonyl]-4-(2-phenylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

10/031367




● HCl

RN 321913-38-6 CAPLUS
CN Piperazine, 1-(2-phenylethyl)-4-[[3-(2-thienyl)-1H-indol-5-yl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 321913-39-7 CAPLUS
CN Piperazine, 1-[(3-benzoyl-1H-indol-4-yl)carbonyl]-4-[2-(4-fluorophenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

10/031367

IT 321913-41-1


RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of piperazinyl indolyl methanones as 5-HT_{2A} receptor antagonists)


RN 321913-41-1 CAPLUS

CN Piperazine, 1-[[3-(4-chlorobenzoyl)-1H-indol-4-yl]carbonyl]-4-[2-(4-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




10/031367

L4 ANSWER 13 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 2001:62284 CAPLUS
DN 134:115969
TI Preparation of indolcarbonylpiperazines as 5-HT_{2A} receptor antagonists.
IN Boettcher, Henning; Greiner, Hartmut; Harting, Juergen; Bartoszyk, Gerd;
Seyfried, Christoph; Amsterdam, Christoph
PA Merck Patent Gmbh, Germany
SO Ger. Offen., 10 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19934433	A1	20010125	DE 1999-19934433	19990722
	WO 2001007435	A2	20010201	WO 2000-EP6464	20000707
	WO 2001007435	A3	20010816		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	BR 2000012607	A	20020409	BR 2000-12607	20000707
	EP 1198453	A2	20020424	EP 2000-949288	20000707
	EP 1198453	B1	20030409		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	JP 2003505458	T2	20030212	JP 2001-512519	20000707
	AT 236877	E	20030415	AT 2000-949288	20000707
	NO 2002000307	A	20020321	NO 2002-307	20020121
PRAI	DE 1999-19934433	A	19990722		
	WO 2000-EP6464	W	20000707		
OS	MARPAT 134:115969				
GI					

Apps PCT



AB Title compds. [I; R₁ = (substituted) Ph; R₄, R₅ = H, cyano, acyl, halo, alkyl, OH; R₄R₅ = C₃-5 alkylene], were prep'd. as 5-HT_{2A} receptor antagonists (no data). Thus, 4-carboxyindole, 2-chloro-1-methylpyridinium iodide, N-phenethylpiperazine, ethyldiisopropylamine, and N-methylpyrrolidine were stirred together for 3 h to give (1H-indol-4-yl)-4-(phenethylpiperazin-1-yl)methanone hydrochloride.

IT 320714-85-0P 320714-86-1P 320714-88-3P
320714-89-4P 320714-93-0P 320714-94-1P
320714-96-3P 320714-97-4P 320714-98-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);


10/031367

BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of indolcarbonylpiperazines as 5-HT_{2A} receptor antagonists)

RN 320714-85-0 CAPLUS


CN Piperazine, 1-(1H-indol-4-ylcarbonyl)-4-(2-phenylethyl)-, hydrochloride
(9CI) (CA INDEX NAME)



●x HCl

RN 320714-86-1 CAPLUS

CN Piperazine, 1-[2-(4-fluorophenyl)ethyl]-4-(1H-indol-4-ylcarbonyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 320714-88-3 CAPLUS


CN Piperazine, 1-[2-(4-fluorophenyl)ethyl]-4-[(3-formyl-1H-indol-5-yl)carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

10/031367




●x HCl

RN 320714-89-4 CAPLUS
CN Piperazine, 1-[2-(4-fluorophenyl)ethyl]-4-(1H-indol-6-ylcarbonyl)-,
hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 320714-93-0 CAPLUS
CN Piperazine, 1-[(3-cyano-1H-indol-6-yl)carbonyl]-4-[2-(4-fluorophenyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 320714-94-1 CAPLUS
CN Piperazine, 1-[2-(4-fluorophenyl)ethyl]-4-(1H-indol-7-ylcarbonyl)-,
hydrochloride (9CI) (CA INDEX NAME)


10/031367



●x HCl

RN 320714-96-3 CAPLUS

CN Piperazine, 1-[2-(4-fluorophenyl)ethyl]-4-[(3-formyl-1H-indol-7-yl)carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 320714-97-4 CAPLUS


CN Piperazine, 1-[(3-cyano-1H-indol-7-yl)carbonyl]-4-[2-(4-fluorophenyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

10/031367





RN 320714-98-5 CAPLUS

CN Piperazine, 1-[(2,3-dimethyl-1H-indol-7-yl)carbonyl]-4-[2-(4-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 2000:842127 CAPLUS
DN 134:17503
TI Preparation of 5-[4-benzylpiperidinyl(piperazinyl)]-indolecarboxamides as
inhibitors of p38 kinase
IN Mavunkel, Babu J.; Chakravarty, Sarvajit; Perumattam, John J.; Dugar,
Sundeep; Lu, Qing; Liang, Xi
PA Scios Inc., USA
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000071535	A1	20001130	WO 2000-US14003	20000519
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1178983	A1	20020213	EP 2000-939322	20000519
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000011274	A	20020226	BR 2000-11274	20000519
	BG 106091	A	20020628	BG 2001-106091	20011108
	NO 2001005655	A	20020118	NO 2001-5655	20011120
PRAI	US 1999-316761	A	19990521		
	US 1999-154594P	P	19990917		
	US 2000-202608P	P	20000509		
	WO 2000-US14003	W	20000519		
OS	MARPAT 134:17503				
GI					




AB The title compds. [I; one Z2 = CA, CR8A and the other = CR1, CR12, NR6, N (wherein R1, R6, R8 = H, noninterfering substituent; A = WiCOXjY; Y = COR2, an isostere; R2 = H, noninterfering substituent; W, X = spacer of 2-6.ANG.; i, j = 0-1); Z3 = NR7, O; R3 = noninterfering substituent; n = 0-3; L1, L2 = linker; R4 = noninterfering substituent; m = 0-4; Z1 = CR5, N (R5 = H, noninterfering substituent); l, k = 0-2, wherein the sum of l and k = 0-3; Ar = aryl substituted with 0-5 noninterfering substituents, wherein two noninterfering substituents can form a fused ring; the distance between the atom of Ar linked to L2 and the center of the ..alpha. ring is 4.5-24.ANG.] which inhibit p38-..alpha. kinase (biol. data given), were prepd. Thus, treating 6-methoxy-(4-benzylpiperidinyl)-indole-5-carboxamide with oxalyl chloride in CH2Cl2 afforded the indole-5-carboxamide II.

IT 309913-41-5P 309913-43-7P 309913-59-5P
 309913-60-8P 309913-64-2P 309913-71-1P
 309913-72-2P 309913-73-3P 309913-74-4P
 309913-82-4P 309913-83-5P 309913-85-7P
 309913-88-0P 309914-02-1P 309914-14-5P
 309914-17-8P 309914-21-4P 309914-25-8P
 309914-27-0P 309914-60-1P 309914-62-3P
 309914-63-4P 309914-64-5P 309914-71-4P
 309914-73-6P 309914-74-7P 309914-77-0P
 309914-78-1P 309914-79-2P 309914-80-5P
 309914-83-8P 309914-85-0P 309914-86-1P
 309914-87-2P 309914-89-4P 309914-95-2P
 309914-96-3P 309914-97-4P 309914-98-5P
 309915-01-3P 309915-02-4P 309915-04-6P
 309915-05-7P 309915-12-6P 309915-13-7P
 309915-14-8P 309915-15-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 5-[4-benzylpiperidinyl(piperazinyl)]-indolecarboxamides as inhibitors of p38 kinase)

RN 309913-41-5 CAPLUS

CN 1H-Indole-3-acetamide, 5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-N,N,1-trimethyl-..alpha.-oxo- (9CI) (CA INDEX NAME)




RN 309913-43-7 CAPLUS


CN 1H-Indole-1-carboxylic acid, 3-[(dimethylamino)oxoacetyl]-5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/031367



RN 309913-59-5 CAPLUS
 CN 1H-Indole-3-acetamide, 6-chloro-5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N,N,1-trimethyl-.alpha.-oxo- (9CI) (CA INDEX NAME)




RN 309913-60-8 CAPLUS
 CN 1H-Indole-1-carboxylic acid, 5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-3-(4-morpholinyl-oxoacetyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 309913-64-2 CAPLUS
 CN 1H-Indole-1-carboxylic acid, 6-chloro-3-[(dimethylamino)oxoacetyl]-5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

10/031367


Relative stereochemistry.



RN 309913-71-1 CAPLUS

CN 1H-Indole-1-carboxylic acid, 3-[(dimethylamino)oxoacetyl]-5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 309913-72-2 CAPLUS

CN 1H-Indole-3-acetamide, 1-[(dimethylamino)carbonyl]-5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-N,N-dimethyl-.alpha.-oxo-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 309913-73-3 CAPLUS

10/031367


CN 1H-Indole-3-acetamide, 1-acetyl-5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-N,N-dimethyl-.alpha.-oxo- (9CI)
(CA INDEX NAME)



RN 309913-74-4 CAPLUS

CN 1H-Indole-3-acetamide, 5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-N,N-dimethyl-1-(methylsulfonyl)-.alpha.-oxo-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 309913-82-4 CAPLUS

CN 1H-Indole-3-acetamide, 1-acetyl-5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-N,N-dimethyl-.alpha.-oxo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 309913-83-5 CAPLUS

CN 1H-Indole-3-acetamide, 6-chloro-5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N,N,1-trimethyl-.alpha.-oxo- (9CI) (CA

10/031367

INDEX NAME)


Absolute stereochemistry.



RN 309913-85-7 CAPLUS

CN 1H-Indole-3-acetamide, 6-chloro-5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-1-methyl-.alpha.-oxo-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 309913-88-0 CAPLUS

CN 1H-Indole-3-acetamide, 6-chloro-5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-1-(methoxymethyl)-N,N-dimethyl-.alpha.-oxo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 309914-02-1 CAPLUS

CN 1H-Indole-3-acetamide, 6-chloro-5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N,1-dimethyl-.alpha.-oxo-, rel- (9CI)

10/031367

(CA INDEX NAME)


Relative stereochemistry.



RN 309914-14-5 CAPLUS

CN 1H-Indole-3-acetamide, 5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-N,N,1-trimethyl-.alpha.-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 309914-17-8 CAPLUS

CN 1H-Indole-3-acetamide, 5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-1-(methoxymethyl)-N,N-dimethyl-.alpha.-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 309914-21-4 CAPLUS

CN Morpholine, 4-[[[6-chloro-5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-1-methyl-1H-indol-3-yl]oxoacetyl]- (9CI) (CA INDEX NAME)

10/031367


Absolute stereochemistry.



RN 309914-25-8 CAPLUS

CN Morpholine, 4-[[5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-1-methyl-1H-indol-3-yl]oxoacetyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 309914-27-0 CAPLUS

CN 1H-Indole-3-acetamide, 6-chloro-5-[[[(2R,5S)-4-[1-(4-fluorophenyl)ethyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N,N,1-trimethyl-.alpha.-oxo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 309914-60-1 CAPLUS

CN 1H-Indole-3-acetic acid, .alpha.-oxo-5-[[4-(phenylmethyl)-1-


10/031367

piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 309914-62-3 CAPLUS

CN 1H-Indole-3-acetic acid, 6-methoxy-.alpha.-oxo-5-[[4-(phenylmethyl)-1-piperazinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 309914-63-4 CAPLUS

CN 1H-Indole-3-acetic acid, .alpha.-oxo-5-[[4-(1-phenylethyl)-1-piperazinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 309914-64-5 CAPLUS


CN Piperazine, 1-[[3-[(4-methyl-1-piperidinyl)oxoacetyl]-1H-indol-5-yl]carbonyl]-4-(1-phenylethyl)- (9CI) (CA INDEX NAME)



10/031367


RN 309914-71-4 CAPLUS

CN 1H-Indole-3-acetamide, 5-[[4-[(3-chlorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N,N-dimethyl-.alpha.-oxo- (9CI) (CA INDEX NAME)




RN 309914-73-6 CAPLUS

CN Piperazine, 1-[(3-chlorophenyl)methyl]-2,5-dimethyl-4-[[3-[(4-methyl-1-piperidinyl)oxoacetyl]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 309914-74-7 CAPLUS


CN 1H-Indole-3-acetamide, 5-[[2,5-dimethyl-4-(1-phenylethyl)-1-piperazinyl]carbonyl]-N,N-dimethyl-.alpha.-oxo- (9CI) (CA INDEX NAME)




RN 309914-77-0 CAPLUS

CN 1H-Indole-3-acetamide, 5-[[[(2R,5S)-2,5-dimethyl-4-(phenylmethyl)-1-piperazinyl]carbonyl]-N,N-dimethyl-.alpha.-oxo-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 309914-78-1 CAPLUS
 CN 1H-Indole-3-acetamide, 5-[[4-[(4-fluorophenyl)methyl]-3-oxo-1-piperazinyl]carbonyl]-N,N-dimethyl-.alpha.-oxo- (9CI) (CA INDEX NAME)




RN 309914-79-2 CAPLUS
 CN 1H-Indole-3-acetamide, 5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-N,N-dimethyl-.alpha.-oxo- (9CI) (CA INDEX NAME)




RN 309914-80-5 CAPLUS
 CN 1H-Indole-3-acetamide, 5-[[[(2R,5S)-4-[(3-chlorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-N,N-dimethyl-.alpha.-oxo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 309914-83-8 CAPLUS

CN 1H-Indole-3-acetamide, 5-[[2,5-dimethyl-4-(1-phenylethyl)-1-piperazinyl]carbonyl]-4-methoxy-N,N-dimethyl-.alpha.-oxo- (9CI) (CA INDEX NAME)




RN 309914-85-0 CAPLUS

CN 1H-Indole-3-acetamide, 5-[[2,5-dimethyl-4-(1-phenylethyl)-1-piperazinyl]carbonyl]-6-methoxy-N,N-dimethyl-.alpha.-oxo- (9CI) (CA INDEX NAME)




RN 309914-86-1 CAPLUS

CN Morpholine, 4-[[5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-1H-indol-3-yl]oxoacetyl]- (9CI) (CA INDEX NAME)



RN 309914-87-2 CAPLUS


CN 1H-Indole-3-acetamide, 6-chloro-5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N,N-dimethyl-.alpha.-oxo- (9CI) (CA INDEX NAME)



RN 309914-89-4 CAPLUS

CN Morpholine, 4-[[[6-chloro-5-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-1H-indol-3-yl]oxoacetyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 309914-95-2 CAPLUS


CN Piperazine, 1-[(4-fluorophenyl)methyl]-4-[[[6-methoxy-3-[(4-methyl-1-piperazinyl)oxoacetyl]-1H-indol-5-yl]carbonyl]-2,5-dimethyl-, (2R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10/031367




RN 309914-96-3 CAPLUS
CN 1H-Indole-3-acetamide, 5-[[2,5-dimethyl-4-(phenylmethyl)-1-piperazinyl]carbonyl]-6-methoxy-N,N-dimethyl-.alpha.-oxo- (9CI) (CA INDEX NAME)



RN 309914-97-4 CAPLUS
CN 1H-Indole-3-acetamide, 5-[[2,5-dimethyl-4-(phenylmethyl)-1-piperazinyl]carbonyl]-6-methoxy-N,N-dimethyl-.alpha.-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 309914-98-5 CAPLUS
CN 1H-Indole-3-acetamide, 5-[[2,5-dimethyl-4-(phenylmethyl)-1-piperazinyl]carbonyl]-6-methoxy-N,N-dimethyl-.alpha.-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/031367



RN 309915-01-3 CAPLUS

CN 1H-Indole-3-acetamide, 6-chloro-5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N,N,2-trimethyl-.alpha.-oxo-, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 309915-02-4 CAPLUS

CN 1H-Indole-3-acetamide, 5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-N,N-dimethyl-.alpha.-oxo-, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 309915-04-6 CAPLUS

CN 1H-Indole-3-acetamide, 5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-N,N,2-trimethyl-.alpha.-oxo-, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.


10/031367



RN 309915-05-7 CAPLUS

CN 1H-Indole-3-acetamide, 5-[[[(2R,5S)-4-[1-(4-fluorophenyl)ethyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-N,N,2-trimethyl-.alpha.-oxo-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 309915-12-6 CAPLUS

CN 1H-Indole-3-acetamide, 6-chloro-5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N,N,1-trimethyl-.alpha.-oxo-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl


RN 309915-13-7 CAPLUS

CN 1H-Indole-3-acetamide, 6-chloro-5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N,N,1-trimethyl-.alpha.-oxo-, rel- (9CI)

10/031367


(CA INDEX NAME)

Relative stereochemistry.



RN 309915-14-8 CAPLUS


CN 1H-Indole-3-acetamide, 5-[[4-[(4-fluorophenyl)methyl]-3-oxo-1-piperazinyl]carbonyl]-6-methoxy-N,N-dimethyl-.alpha.-oxo- (9CI) (CA INDEX NAME)



RN 309915-15-9 CAPLUS

CN 1H-Indole-3-acetamide, 5-[[[(2R,5S)-2,5-dimethyl-4-(1-phenylethyl)-1-piperazinyl]carbonyl]-6-methoxy-N,N-dimethyl-.alpha.-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 309915-19-3P 309915-24-0P 309915-38-6P
309915-41-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


10/031367

(prepn. of 5-[4-benzylpiperidinyl(piperazinyl)]-indolecarboxamides as inhibitors of p38 kinase)

RN 309915-19-3 CAPLUS

CN Piperazine, 1-[(6-chloro-1-methyl-1H-indol-5-yl)carbonyl]-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-, (2R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 309915-24-0 CAPLUS


CN Piperazine, 1-[(6-chloro-1-methyl-1H-indol-5-yl)carbonyl]-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-, (2R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 309915-38-6 CAPLUS

CN Piperazinone, 1-[(4-fluorophenyl)methyl]-4-[(6-methoxy-1H-indol-5-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 309915-41-1 CAPLUS

CN Piperazine, 1-[(6-methoxy-1H-indol-5-yl)carbonyl]-2,5-dimethyl-4-(1-phenylethyl)-, (2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/031367



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 25 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:627999 CAPLUS
 DN 133:222744
 TI Preparation of 1-acyl-4-cyanobenzylimidazolylmethylpiperazines and related compounds as inhibitors of prenyl-protein transferases.
 IN Stump, Craig A.; Williams, Theresa M.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 122 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000051614	A1	20000908	WO 2000-US5354	20000301
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1165084	A1	20020102	EP 2000-910386	20000301
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	JP 2002538121	T2	20021112	JP 2000-602082	20000301
PRAI	US 1999-122971P	P	19990303		
	US 1999-127252P	P	19990331		
	WO 2000-US5354	W	20000301		
OS	MARPAT 133:222744				
GI					



I

AB Title compds. I; R1a, R1b = H, aryl, heterocyclyl, cycloalkyl, alkenyl, alkynyl, (substituted) alkyl, etc.; R8 = H, (substituted) aryl, heterocyclyl, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, N3, NO2, cyano, etc.; R9 = H, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, (substituted) alkyl, etc.; A1, A2 = bond, CH:CH, C.tplbond.C, CO, O, S, SO, SO2, etc.; A3 = CO, S, SO, SO2; V = H, heterocyclyl, aryl, alkyl, alkenyl; W = heterocyclyl; Z = (substituted) aryl, heteroaryl; Q = (CH2)s; Q1 = (R8)mVA1[C(R1a)2]nA2[C(R1a)2]nW(R9)q[C(R1b)2]p; m = 0-5; n, p = 0-4; q = 1, 2; s = 0, 1; with provisos, were prepd. Thus, 1-[1-(4-cyanobenzyl)imidazol-5-ylmethyl]piperazine trihydrochloride, 2-methoxyquinoline-4-carboxylic acid, EDC hydrochloride, hydroxybenzotriazole, and EtN(CHMe2)2 were stirred in DMF to give 4-[1-(4-cyanobenzyl)imidazol-5-ylmethyl]-1-(2-methoxyquinolin-4-oyl)piperazine trihydrochloride. Tested I inhibited human farnesyl protein transferase with IC50.ltoreq.5 .mu.M.

IT 290819-45-3P 290819-75-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

10/031367

BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1-acyl-4-cyanobenzylimidazolymethylpiperazines and related
comps. as inhibitors of prenyl-protein transferases)


RN 290819-45-3 CAPLUS

CN Piperazine, 1-[[1-[(4-cyanophenyl)methyl]-1H-imidazol-5-yl]methyl]-4-(1H-indol-4-ylcarbonyl)- (9CI) (CA INDEX NAME)



RN 290819-75-9 CAPLUS

CN Piperazine, 1-[[1-[(4-cyanophenyl)methyl]-1H-imidazol-5-yl]methyl]-4-(1H-indol-4-ylcarbonyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/031367

L4 ANSWER 16 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 2000:384179 CAPLUS
DN 133:30741
TI Substituted piperazinone derivatives and other oxoazaheterocycl
compounds useful as factor Xa inhibitors
IN Ewing, William R.; Becker, Michael R.; Myers, Michael R.; Spada, Alfred P.
PA Aventis Pharmaceuticals Products Inc., USA
SO PCT Int. Appl., 219 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000032590	A1	20000608	WO 1999-US28074	19991124
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	WO 9937304	A1	19990729	WO 1999-US1682	19990127
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1998-110012P	A2	19981125		
	WO 1999-US1682	A2	19990127		
	US 1999-313611	A2	19990518		
	US 1999-363196	A2	19990728		
	US 1998-72707P	A2	19980127		
OS	MARPAT 133:30741				
GI					



I



II

AB The invention is directed to piperazinones I and their pharmaceutically acceptable salts, prodrugs, N-oxides, hydrates, and solvates [wherein R1 = H, alkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, alkoxy, aminoalkyl, CH2OZ, CH(CH3)OZ; R2 = H, (un)substituted alkyl, aryl, aralkyl, heteroaryl, or heteroarylalkyl; R3 = H or Me; X = N or O; Z = lower alkyl or alkoxyalkyl; Cy1 = (un)substituted aryl, (un)substituted heteroaryl; Cy2 = (un)substituted aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, etc.]. The compds. inhibit factor Xa (no data), and thereby the prodn. of thrombin, and are thus useful as anticoagulants in the treatment of a wide variety of conditions. The invention is also directed to pharmaceutical compns., synthetic intermediates, and a method of inhibiting factor Xa. Examples include the synthesis of approx. 780 invention compds., approx. 50 of which are also claimed, and several hundred intermediates. For instance, condensation of 5-chloro-2-thienyloxyacetic acid with the corresponding N-benzyloxycarbonyl-protected piperazinone deriv. (preps. given), using DIPEA and TBTU in DMF, gave the preferred title compd. II.


IT 234102-35-3P 234102-92-2P 234103-21-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of piperazinone derivs. and other substituted oxoazaheterocyclyl compds. as factor Xa inhibitors)

RN 234102-35-3 CAPLUS

CN Piperazinone, 1-[(4-amino-7-quinazolinyl)methyl]-4-[(3-chloro-1H-indol-6-yl)carbonyl]- (9CI) (CA INDEX NAME)




10/031367

RN 234102-92-2 CAPLUS

CN Piperazinone, 1-[(4-amino-7-quinazolinyl)methyl]-4-[(3-chloro-1H-indol-6-yl)carbonyl]-3-methyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 234103-21-0 CAPLUS

CN Piperazinone, 1-[(4-amino-7-quinazolinyl)methyl]-4-[(3-chloro-1H-indol-6-yl)carbonyl]-3-ethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/031367

L4 ANSWER 17 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 2000:161119 CAPLUS
DN 132:203174
TI Inhibitors of p38-.alpha. kinase, preparation thereof, and therapeutic use
IN Goehring, R. Richard; Luedtke, Gregory R.; Mavunkel, Babu J.; Chakravarty, Sarvajit; Dugar, Sundeeep; Schreiner, George F.; Liu, David Y.; Lewicki, John A.
PA Scios Inc., USA
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000012074	A2	20000309	WO 1999-US19845	19990827
	WO 2000012074	A3	20000831		
	W:	AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, EE, GE, HU, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2342251	AA	20000309	CA 1999-2342251	19990827
	AU 9957936	A1	20000321	AU 1999-57936	19990827
	EP 1107758	A2	20010620	EP 1999-945316	19990827
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 9913654	A	20011127	BR 1999-13654	19990827
	JP 2002523448	T2	20020730	JP 2000-567192	19990827
PRAI	US 1998-98219P	P	19980828 ←		
	US 1999-125343P	P	19990319		
	US 1998-125343P	P	19990319		
	WO 1999-US19845	W	19990827		
OS	MARPAT 132:203174				
GI					



AB Methods are provided for treating conditions mediated by p38-.alpha. kinase using compds. I (Z = N, CR1; R1 = noninterfering substituent; X1, X2 = linker; Ar1, Ar2 = (un)substituted C1-20 hydrocarbyl (at least one of Ar1 and Ar2 = (un)substituted aryl), with proviso that when X2 = CH2 or an isostere thereof, X1 = CO or an isostere thereof, and Ar2 = (un)substituted Ph, Ar1 is other than (un)substituted indolyl, benzimidazolyl or benzotriazolyl, and wherein (un)substituted Ph is not (un)substituted indolyl, benzimidazolyl, or benzotriazolyl; Y = noninterfering substituent; n, m = 0-4; l = 0-3) or a pharmaceutically acceptable salt or pharmaceutical compn. thereof. Prepn. of compds. is

10/031367

described. Compds. of the invention may be used to treat p38-.alpha. kinase-mediated conditions.


IT 260427-31-4 260427-72-3 260427-75-6
260427-76-7 260427-91-6 260427-92-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(p38-.alpha. kinase inhibitors, prepn., and therapeutic use)


RN 260427-31-4 CAPLUS

CN Piperazine, 1-[(4-fluorophenyl)methyl]-4-(1H-indol-4-ylcarbonyl)- (9CI)
(CA INDEX NAME)



RN 260427-72-3 CAPLUS


CN Piperazine, 1-(1H-indol-6-ylcarbonyl)-4-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 260427-75-6 CAPLUS


CN Piperazine, 1-(1H-indol-4-ylcarbonyl)-4-(1-phenylethyl)- (9CI) (CA INDEX NAME)

10/031367




RN 260427-76-7 CAPLUS

CN Piperazine, 1-[(3-chlorophenyl)methyl]-4-(1H-indol-4-ylcarbonyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 260427-91-6 CAPLUS

CN Piperazine, 1-(1H-indol-5-ylcarbonyl)-4-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 260427-92-7 CAPLUS

CN Piperazine, 1-[(6-methoxy-1H-indol-5-yl)carbonyl]-4-(1-phenylethyl)- (9CI)

10/031367



(CA INDEX NAME)



10/031367

L4 ANSWER 18 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 1999:764025 CAPLUS
DN 132:3363
TI Heterocyclic compounds and methods to treat cardiac failure and other disorders
IN Mavunkel, Babu J.; Liu, David Y.; Schreiner, George F.; Lewicki, John A.; Perumattam, John J.
PA Scios, Inc., USA
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9961426	A1	19991202	WO 1999-US11222	19990521
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6130235	A	20001010	US 1998-128137	19980803
	US 6340685	B1	20020122	US 1999-275176	19990324
	AU 9940920	A1	19991213	AU 1999-40920	19990521
	BR 9911069	A	20010206	BR 1999-11069	19990521
	EP 1080078	A1	20010307	EP 1999-924412	19990521
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	JP 2002516314	T2	20020604	JP 2000-550832	19990521
	NO 2000005881	A	20010109	NO 2000-5881	20001121
PRAI	US 1998-86531P	P	19980522		
	US 1998-128137	A	19980803		
	US 1999-275176	A	19990324		
	WO 1999-US11222	W	19990521		
OS	MARPAT 132:3363				
GI					



AB Compds. I and II [Z1, Z2 = CR₄, N; R₄ = H, alkyl, aryl, each of said alkyl


or aryl optionally including one or more heteroatoms selected from O, S and N and optionally substituted by one or more of halo, OR, SR, NR₂, RCO, CO₂R, CONR₂, O₂CR, NROCR and R = H, alkyl, CN, oxo, etc.; R₁ = Q and X₁ = CO or an isostere; m = 0, 1; Y = alkyl, aryl, arylalkyl; YY = alkylene bridge; n = 0, 2; Z₃ = CH, N; X₂ = CH, CH₂ or an isostere; Ar = one or two Ph moieties directly coupled to X₂ optionally substituted by halo, nitro, alkyl, etc.; R₂ = H, alkyl, aryl; R₃ = H, halo, NO₂, alkyl, alkenyl, etc.], selective inhibitors of p38.alpha. kinase, were prepd. E.g., 4-benzylpiperidinylindole-5-carboxamide was prepd.

IT 251106-48-6P 251106-62-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclic compds. as selective inhibitors of p38 kinase)


RN 251106-48-6 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)methyl]-4-[[1-(1-methylethyl)-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 251106-62-4 CAPLUS

CN Piperazine, 1-[(1-ethyl-1H-indol-5-yl)carbonyl]-4-(phenylmethyl)- (9CI)
(CA INDEX NAME)




IT 251107-28-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of heterocyclic compds. as selective inhibitors of p38 kinase)

RN 251107-28-5 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)methyl]-4-(1H-indol-5-ylcarbonyl)- (9CI)
(CA INDEX NAME)




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/031367

L4 ANSWER 19 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 1999:487215 CAPLUS
DN 131:130007
TI Substituted piperazinone derivatives and other oxoazaheterocycl
compounds useful as factor Xa inhibitors
IN Ewing, William R.; Becker, Michael R.; Choi-Sledeski, Yong Mi; Pauls,
Heinz W.; He, Wei; Condon, Stephen M.; Davis, Roderick S.; Hanney, Barbara
A.; Spada, Alfred P.; Burns, Christopher J.; Jiang, John Z.; Li, Aiwen;
Myers, Michael R.; Lau, Wan F.; Poli, Gregory B.
PA Rhone-Poulenc Rorer Pharmaceuticals Inc., USA
SO PCT Int. Appl., 300 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9937304	A1	19990729	WO 1999-US1682	19990127
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9900607	A	19990727	ZA 1999-607	19990127
	CA 2319198	AA	19990729	CA 1999-2319198	19990127
	AU 9926533	A1	19990809	AU 1999-26533	19990127
	AU 745425	B2	20020321		
	BR 9907300	A	20001024	BR 1999-7300	19990127
	EP 1051176	A1	20001115	EP 1999-906684	19990127
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002501024	T2	20020115	JP 2000-528286	19990127
	EE 200000435	A	20020215	EE 2000-435	19990127
	WO 2000032590	A1	20000608	WO 1999-US28074	19991124
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	NO 2000003808	A	20000926	NO 2000-3808	20000725
PRAI	US 1998-72707P	A2	19980127		
	US 1998-110012P	A2	19981125		
	WO 1999-US1682	W	19990127		
	US 1999-313611	A2	19990518		
	US 1999-363196	A2	19990728		
OS	MARPAT 131:130007				
GI					




AB The invention is directed to oxoazaheterocyclyl compds. I and their pharmaceutically acceptable salts, prodrugs, N-oxides, hydrates, and solvates [wherein A = CH, N; G1, G2 = (independently) -L-Cy; L = various at. and mol. linkers, including O, (un)substituted NH or S, alk(en/yn)ylene, etc., or their combinations; Cy = (un)substituted (hetero)aryl, cycloalk(en)yl, heterocyclyl, etc.; R = (independently) H, CO₂H, alkoxycarbonyl, (un)substituted carbamoyl, alkyl, (hetero)aryl, (hetero)aralkyl; or two geminal R groups = O or S; m, n = 0-2; with provisos]. The compds. inhibit factor Xa (no data), and thereby the prodn. of thrombin, and are thus useful as anticoagulants in the treatment of a wide variety of conditions. The invention is also directed to pharmaceutical compns., synthetic intermediates, and a method of inhibiting factor Xa. Examples include the synthesis of approx. 780 compds. I, which are also claimed, and several hundred intermediates. For instance, sulfonamidation of 6-chlorobenzo[b]thiophene-2-sulfonyl chloride with 4-(2-oxopiperazin-1-ylmethyl)benzamidinium bistrifluoroacetate (preps. given) in CH₂Cl₂ in the presence of Et₃N gave title compd. II.

IT 234102-35-3P 234102-92-2P 234103-21-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of piperazinone derivs. and other substituted oxoazaheterocyclyl compds. as factor Xa inhibitors)

RN 234102-35-3 CAPLUS

CN Piperazinone, 1-[(4-amino-7-quinazolinyl)methyl]-4-[(3-chloro-1H-indol-6-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 234102-92-2 CAPLUS

CN Piperazinone, 1-[(4-amino-7-quinazolinyl)methyl]-4-[(3-chloro-1H-indol-6-yl)carbonyl]-3-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/031367



RN 234103-21-0 CAPLUS

CN Piperazinone, 1-[(4-amino-7-quinazolinyl)methyl]-4-[(3-chloro-1H-indol-6-yl)carbonyl]-3-ethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/031367

L4 ANSWER 20 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 1991:583313 CAPLUS
DN 115:183313
TI Preparation and formulation of benzofurazan derivatives as antiarrhythmics
IN Baldwin, John J.; Claremon, David A.; Elliott, Jason M.; Ponticello, Gerald S.; Remy, David C.; Selnick, Harold G.
PA Merck and Co., Inc., USA
SO Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 431944	A2	19910612	EP 1990-313263	19901206
	EP 431944	A3	19920115		
	R: CH, DE, FR, GB, IT, LI, NL				
	US 5032604	A	19910716	US 1989-447941	19891208
	JP 03209372	A2	19910912	JP 1990-326193	19901129
	CA 2031645	AA	19910609	CA 1990-2031645	19901206
	US 5112824	A	19920512	US 1991-730332	19910715
PRAI	US 1989-447941		19891208		
OS	MARPAT 115:183313				
GI					



AB The title compds. I [Q = NR, 5- to 7-membered heterocycle with 1 or 2 N atoms; R = H, alkyl; X, Y = CO, (CRR)m, SO2, bond, etc.; m = 1 to 3; E = O, S; r = 0 or 1; R1 = H, Q1, Q2, etc.; R2, R3 = H, alkoxy, NO2, halo, cyano, etc.] were prepd. I are antiarrhythmics with potassium blocking activity. Reaction of alc. II with methanesulfonyl chloride, followed by reaction with 1-(4-pyridyl)piperazine, gave benzofuran III. The effective concns. of compds. I required to increase the refractory period (in isolated papillary muscle) by an increment of 25% above baseline is

10/031367


.ltoreq.10 .mu.M.

IT 136482-01-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as antiarrhythmic)

RN 136482-01-4 CAPLUS


CN Piperazine, 1-[2-(2,1,3-benzoxadiazol-5-yl)ethyl]-4-(1H-indol-5-ylcarbonyl)- (9CI) (CA INDEX NAME)



10/031367

L4 ANSWER 21 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 1991:559163 CAPLUS
DN 115:159163
TI Preparation 1-(hetero)cycloalkyl-4-(2-arylethyl)piperazines and analogs as
antiarrhythmic agents
IN Baldwin, John J.; Claremon, David A.; Elliott, Jason M.; Ponticello,
Gerald S.; Remy, David C.; Selnick, Harold G.
PA Merck and Co., Inc., USA
SO Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 431945	A2	19910612	EP 1990-313264	19901206
	EP 431945	A3	19920422		
	R: CH, DE, FR, GB, IT, LI, NL				
	US 5032598	A	19910716	US 1989-447949	19891208
	JP 03181461	A2	19910807	JP 1990-326194	19901129
	CA 2031693	AA	19910609	CA 1990-2031693	19901206
	US 5215989	A	19930601	US 1991-730317	19910715
PRAI	US 1989-447949		19891208		
OS	MARPAT 115:159163				
GI					



II


AB ArXQYR1 [I; Ar = (un)substituted benzo-, thieno-, furo-, or pyrrolo-fused Ph or other 5 to 7-membered carbocyclic or heterocyclic moiety; Q = 5 to 7-membered heterocyclenylenediyl; R1 = H when Q = imidazolylenediyl; R1 is otherwise (un)substituted (hetero)aryl; X = CO, CONR(CR2)m, SO2, (CR2)m; R = H, C1-6 alkyl; Y = (CR2)m, (CR2)mO; m = 0-3] were prepd. Thus, thiochroman-4-ol was treated with SOCl2 and the product condensed with 4-[2-(2-pyridyl)ethyl]piperazine to give title compd. II. I at .ltoreq.10 .mu.M gave a 25% increase of isolated ferret papillary muscle refractory period.

IT 136188-74-4P 136188-75-5P 136188-76-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as antiarrhythmic agent)

RN 136188-74-4 CAPLUS
CN Piperazine, 1-(1H-indol-5-ylcarbonyl)-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)


10/031367

excl.




RN 136188-75-5 CAPLUS

CN Piperazine, 1-(1H-indol-5-ylcarbonyl)-4-[2-[4-
[(methylsulfonyl)amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 136188-76-6 CAPLUS

CN Piperazine, 1-(1H-indol-5-ylcarbonyl)-4-[2-(4-nitrophenyl)ethyl]- (9CI)
(CA INDEX NAME)




L4 ANSWER 22 OF 25 CAPLUS COPYRIGHT 2003 ACS
 AN 1991:101745 CAPLUS
 DN 114:101745
 TI Preparation and formulation of 3-[(4-aryl-1,2,3,6-tetrahydropyrido)alkyl]indoles and analogs as nervous system agents
 IN Boettcher, Henning; Juraszyk, Horst; Hausberg, Hans Heinrich; Greiner, Hartmut; Seyfried, Christoph; Minck, Klaus Otto; Bergmann, Rolf
 PA Merck Patent G.m.b.H., Germany
 SO Ger. Offen., 15 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3907974	A1	19900913	DE 1989-3907974	19890311
	EP 387603	A1	19900919	EP 1990-103842	19900228
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	JP 02273672	A2	19901108	JP 1990-49703	19900302
	AU 9051162	A1	19900913	AU 1990-51162	19900308
	AU 622291	B2	19920402		
	CA 2011834	AA	19900911	CA 1990-2011834	19900309
	ZA 9001857	A	19901228	ZA 1990-1857	19900309
	HU 56088	A2	19910729	HU 1990-1382	19900309
	HU 206207	B	19920928		
PRAI	DE 1989-3907974		19890311		
OS	MARPAT 114:101745				
GI					



I



II


AB The title compds. [I; R = OCH₂COR₁, NHR₂, NO₂, CONR₃R₄, CSNH₂; R₁ = OH, NH₂, alkoxy, (di)alkylamino, etc.; R₂ = H, alkanoyl, aroyl, CONH₂, etc.; R₃ = H, (hydroxy)alkyl; R₄ = O-(un)substituted hydroxyalkyl, dialkylamino, (un)substituted Ph, etc.; NR₃R₄ = heterocyclyl; R₇ = 2- or 3-thienyl, (un)substituted Ph; Z = (CH₂)₂₋₅, CH₂SONCH₂CH₂; n = 0-2] were prepd. as nervous system agents (no data). Thus, 3-(4-chlorobutyl)-5-indolylurea [prepn. starting from 5-nitroindole and Cl(CH₂)₃COCl described] was stirred 12 h with 4-phenyl-1,2,3,6-tetrahydropyridine in MeCN to give title compd. II. Pharmaceutical formulations comprising I are given.

IT 132285-58-6P 132285-61-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as nervous system agent)

RN 132285-58-6 CAPLUS


10/031367

CN Piperazine, 1-[[3-[4-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)butyl]-1H-indol-5-yl]carbonyl]-4-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)



RN 132285-61-1 CAPLUS


CN Piperazine, 1-[[3-[4-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)butyl]-1H-indol-5-yl]carbonyl]-4-[2-(1-pyrrolidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)



10/031367

L4 ANSWER 23 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 1989:625318 CAPLUS
DN 111:225318
TI Preparation of 1,4-disubstituted piperazines and their use as antagonists
of platelet-activating factor
IN Sugihara, Hirosada; Itoh, Katsumi; Nishikawa, Kohei
PA Takeda Chemical Industries, Ltd., Japan
SO Eur. Pat. Appl., 35 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 318235	A2	19890531	EP 1988-311022	19881122
	EP 318235	A3	19910502		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 01230570	A2	19890914	JP 1988-295244	19881122
	US 4937246	A	19900626	US 1988-274975	19881122
PRAI	JP 1987-296887		19871125		
GI					



AB The title compds. I [A = (un)substituted Ph, (un)substituted heterocyclyl;
X = CH2, C(:O), C(:S); R1, R2, R3 = lower alkyl] or their salts, a means
of their prepn., and compns. contg. them are provided for inhibition of
platelet-activating factor (PAF). 1-(3-Methoxy-5-nitro-4-propoxybenzoyl)-
4-(3,4,5-trimethoxybenzyl)piperazine-HCl (II) was prepd. from
1-(3,4,5-trimethoxybenzyl)piperazine dihydrochloride and
3-methoxy-5-nitro-4-propoxy-benzoyl chloride (prepn. given). II (3
.times. 10-5M) completely inhibited PAF-induced aggregation of rabbit
platelets; 30 mg II/kg inhibited PAF-induced hypotension in rats.

IT 123947-42-2P 123947-43-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as inhibitor of platelet-activating factor)

RN 123947-42-2 CAPLUS
CN Piperazine, 1-(1H-indol-5-ylcarbonyl)-4-[(3,4,5-trimethoxyphenyl)methyl]-
(9CI) (CA INDEX NAME)



RN 123947-43-3 CAPLUS


10/031367

CN Piperazine, 1-(1H-indol-5-ylcarbonyl)-4-[(3,4,5-trimethoxyphenyl)methyl]-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 123947-42-2

CMF C23 H27 N3 O4




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



10/031367

L4 ANSWER 24 OF 25 CAPLUS COPYRIGHT 2003 ACS
AN 1989:57613 CAPLUS
DN 110:57613
TI Studies on positive inotropic agents. V. Synthesis of
1-heteroaroylpiperazine derivatives
AU Ogawa, Hidenori; Tamada, Shigeharu; Fujioka, Takafumi; Teramoto, Shuji;
Kondo, Kazumi; Yamashita, Shuji; Yabuuchi, Youichi; Tominaga, Michiaki;
Nakagawa, Kazuyuki
CS Tokushima Res. Inst., Otsuka Pharm. Co., Ltd., Tokushima, 771-01, Japan
SO Chemical & Pharmaceutical Bulletin (1988), 36(6), 2253-8
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
OS CASREACT 110:57613
GI




AB A series of title compds. I [X = S, CH₂, CH₂NMe, CONMe, R = PhCH₂, Me₂CHCH₂, PhCO(CH₂)₃] was synthesized and examd. for pos. inotropic activities on the canine heart. The key intermediates, heteroarene carboxylic acids II (X = as above) were prepd. by two different methods, and were conducted with substituted piperazines to give I. The 5-membered lactams prepd. were less active than the control compd. (amrinone). However, the 6-membered cyclic ureido compds., I [X = CH₂NMe, CONMe, CONMe; R = PhCO(CH₂)₃, PhCH₂] all showed potent pos. inotropic activity.

IT 102358-72-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn., inotropic and chronotropic activity of)

RN 102358-72-5 CAPLUS

CN Piperazine, 1-[(2,3-dihydro-2-oxo-1H-indol-5-yl)carbonyl]-4-(phenylmethyl)-
(9CI) (CA INDEX NAME)



10/031367

=> file caold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
110.12	258.90

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-15.62	-15.62

CA SUBSCRIBER PRICE

FILE 'CAOLD' ENTERED AT 17:04:13 ON 18 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l3

L5 0 L3

=> log h

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.40	259.30

FULL ESTIMATED COST



DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-15.62

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 17:04:26 ON 18 MAY 2003



chain nodes :

16 17 19 20

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

chain bonds :

11-16 14-19 16-17 19-20

ring bonds :

1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 10-11 10-15 11-12 11-16 12-13 13-14 14-15 14-19 16-17
19-20

normalized bonds :

4-6 5-9 6-7 7-8 8-9

isolated ring systems :

containing 1.:

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:Atom